Argus upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a research report released on Tuesday, BenzingaRatingsTable reports. They currently have $430.00 target price on the biopharmaceutical company’s stock.
REGN has been the subject of a number of other reports. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a report on Friday, February 7th. They issued a hold rating and a $400.00 target price for the company. BidaskClub upgraded Regeneron Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, February 5th. SunTrust Banks upped their price objective on Regeneron Pharmaceuticals to $400.00 and gave the stock a hold rating in a research report on Friday, February 7th. Credit Suisse Group upgraded Regeneron Pharmaceuticals from a neutral rating to an outperform rating and set a $400.00 price objective on the stock in a research report on Friday, December 13th. Finally, Oppenheimer increased their target price on Regeneron Pharmaceuticals from to and gave the company an outperform rating in a research report on Wednesday, January 22nd. Thirteen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $394.30.
REGN stock opened at $399.55 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.84 and a quick ratio of 2.46. The business has a 50-day moving average price of $370.46 and a 200 day moving average price of $330.44. The company has a market capitalization of $43.87 billion, a P/E ratio of 21.64, a PEG ratio of 1.06 and a beta of 1.24. Regeneron Pharmaceuticals has a 1-year low of $271.37 and a 1-year high of $442.00.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $7.50 earnings per share for the quarter, beating the consensus estimate of $6.03 by $1.47. The firm had revenue of $2.17 billion during the quarter, compared to the consensus estimate of $2.10 billion. Regeneron Pharmaceuticals had a return on equity of 24.14% and a net margin of 26.91%. The firm’s quarterly revenue was up 12.6% on a year-over-year basis. During the same period in the previous year, the company posted $6.84 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals will post 22.34 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, November 5th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to buy up to 2.9% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.
In other news, Chairman P Roy Vagelos sold 22,149 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $363.83, for a total transaction of $8,058,470.67. Also, EVP Andrew J. Murphy sold 8,000 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $340.91, for a total value of $2,727,280.00. Following the sale, the executive vice president now directly owns 57,751 shares in the company, valued at approximately $19,687,893.41. The disclosure for this sale can be found here. Insiders sold a total of 104,679 shares of company stock valued at $38,681,248 in the last quarter. Company insiders own 11.84% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Hong Kong Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $182,000. Advisors Asset Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 18.9% in the fourth quarter. Advisors Asset Management Inc. now owns 20,787 shares of the biopharmaceutical company’s stock valued at $7,805,000 after buying an additional 3,297 shares in the last quarter. Captrust Financial Advisors boosted its stake in shares of Regeneron Pharmaceuticals by 253.4% in the fourth quarter. Captrust Financial Advisors now owns 735 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 527 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Regeneron Pharmaceuticals by 115.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 21,806 shares of the biopharmaceutical company’s stock valued at $8,188,000 after buying an additional 11,665 shares in the last quarter. Finally, Orion Portfolio Solutions LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $59,000. Institutional investors own 66.42% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: What is the definition of a trade war?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.